Research

Posted: Feb 11, 2015 by ITOG Administrator

ITOG Trial #1 Completes Enrollment

The first clinical trial initiated by ITOG in the fall of 2013 has completed its planned enrollment, marking a major accomplishment for ITOG.  The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had...

Posted: Apr 12, 2014 by Yariv Houvras

ITOG Investigators Identify Novel Mutations in Thyroid Cancers That Could Lead to New Therapies

Recent publications from the laboratories of three separate ITOG members have reported the presence of a new type of mutation in certain thyroid cancers that could lead to use of specific use of certain drugs targeting that genetic abnormality.  Mutations in the gene ALK have previously been...

Posted: Apr 2, 2014 by Yariv Houvras

Update on ITOG’s First Clinical Trial

ITOG's first clinical trial has reached 50% of patient accrual. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University,examines whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with Cabozantinib.

Posted: Feb 3, 2014 by Yariv Houvras

Lenvatinib Extends PFS in Differentiated Thyroid Cancer

The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.

Posted: Jun 13, 2013 by Yariv Houvras

Sorafenib Improves Thyroid Cancer Outcomes

(ASCO, June 2, 2013) A large phase III clinical trial reported that sorafenib improves progression free survival for patients with radioactive iodine refractory, differentiated thyroid cancer.

Posted: Jun 11, 2013 by Yariv Houvras

Medullary thyroid cancer : Mutations predict response to oral chemotherapy

For advanced non-resectable MTC (medullary thyroid cancer), there are now two FDA-approved drugs, vandetanib (Caprelsa) and cabozantinib (Cometriq).  At the 2013 American Society of Clinical Oncology meeting in Chicago, ITOG investigators working with Exelixis, Inc.

Posted: Apr 18, 2013 by Yariv Houvras

ITOG Opens First Clinical Trial

ITOG is poised to open it’s first clinical trial for treatment of differentiated thyroid cancer. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, will examine whether patients who had progression of their thyroid cancer on a VEGR inhibitor benefit from...

Posted: Mar 31, 2012 by Yariv Houvras

ITOG Enters Collaborative Agreement With ACCRU to Perform Clinical Trials

ITOG leaders sign Collaborative Agreement with ACCRU.
March, 2012: The ITOG Board of Directors endorsed a partnership with Academic and Community Cancer Research United (ACCRU) an affiliate of Mayo Clinic, Rochester, to conduct clinical trials.  ACCRU was selected after an extensive search to identify a partner to provide robust infrastructure...

Pages

Contact

International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495